Benzinga's Top Ratings Upgrades, Downgrades For June 22, 2023

By Benzinga Insights


For DiaMedica Therapeutics Inc (NASDAQ: DMAC ), Oppenheimer upgraded the previous rating of Perform to Outperform. In the first quarter, DiaMedica Therapeutics showed an EPS of $0.20, compared to $0.13 from the year-ago quarter. At the moment, the stock

You are viewing a robot-friendly page.Click hereto reload in standard format.